DK0721335T3 - Orale suspensioner med höj dosis af mycophenolat-mofetil - Google Patents

Orale suspensioner med höj dosis af mycophenolat-mofetil

Info

Publication number: DK0721335T3
Authority: DK; Denmark
Prior art keywords: high dose; mycophenolate mofetil; oral suspensions; dose oral; agent
Prior art date: 1993-10-01

Application number

DK94929902T

Other languages

English (en)

Inventor

Deborah M Lidgate

Li-Hua Wang-Kessler

Bindu Joshi

Sayee G Hegde

Leo Gu

Original Assignee

Roche Palo Alto Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-01

Filing date

1994-09-27

Publication date

2006-01-09

1994-09-27 Application filed by Roche Palo Alto Llc filed Critical Roche Palo Alto Llc

2006-01-09 Application granted granted Critical

2006-01-09 Publication of DK0721335T3 publication Critical patent/DK0721335T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Virology (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Cosmetics (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Harvesting Machines For Root Crops (AREA)

DK94929902T 1993-10-01 1994-09-27 Orale suspensioner med höj dosis af mycophenolat-mofetil DK0721335T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13034393A	1993-10-01	1993-10-01

Publications (1)

Publication Number	Publication Date
DK0721335T3 true DK0721335T3 (da)	2006-01-09

Family

ID=22444241

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94929902T DK0721335T3 (da)	1993-10-01	1994-09-27	Orale suspensioner med höj dosis af mycophenolat-mofetil

Country Status (28)

Country	Link
US (1)	US5688529A (da)
EP (2)	EP0721335B1 (da)
JP (1)	JP3844491B2 (da)
CN (1)	CN1089583C (da)
AT (1)	ATE303143T1 (da)
AU (1)	AU678303B2 (da)
BR (1)	BR9407728A (da)
CZ (2)	CZ291231B6 (da)
DE (1)	DE69434474T2 (da)
DK (1)	DK0721335T3 (da)
ES (1)	ES2248793T3 (da)
FI (2)	FI116773B (da)
HK (1)	HK1012583A1 (da)
HU (1)	HU228672B1 (da)
IL (1)	IL111116A (da)
LT (1)	LT4099B (da)
LV (1)	LV11428B (da)
NO (1)	NO310673B1 (da)
NZ (1)	NZ274678A (da)
PL (1)	PL177323B1 (da)
PT (1)	PT721335E (da)
RO (1)	RO115412B1 (da)
RU (1)	RU2150942C1 (da)
SG (1)	SG55007A1 (da)
TW (1)	TW427914B (da)
UA (1)	UA39962C2 (da)
WO (1)	WO1995009626A1 (da)
ZA (1)	ZA947683B (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6436425B1 (en)	1988-11-16	2002-08-20	Mdv Technologies, Inc.	Method and non-gelling composition for inhibiting post-surgical adhesions
US5346703A (en)	1990-08-07	1994-09-13	Mediventures, Inc.	Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US5843470A (en)	1995-10-06	1998-12-01	Mdv Technologies, Inc.	Method and composition for inhibiting post-surgical adhesions
ID18663A (id) *	1996-04-12	1998-04-30	Novartis Ag	Komposisi farmasi berlapis enterik
US5759579A (en) *	1996-12-05	1998-06-02	American Home Products Corporation	Pharmaceutical suspension systems
CA2316248A1 (en) *	1997-12-23	1999-07-01	Alliance Pharmaceutical Corp.	Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
JP2002524502A (ja) *	1998-09-14	2002-08-06	バーテックスファーマシューティカルズインコーポレイテッド	ウイルス性疾患の処置法
US6410255B1 (en) *	1999-05-05	2002-06-25	Aurora Biosciences Corporation	Optical probes and assays
NZ515675A (en)	1999-05-14	2004-06-25	Nereus Pharmaceuticals Inc	Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
US6726922B1 (en)	1999-06-28	2004-04-27	Minu, L.L.C.	Process and composition for temporarily suppressing pain
ATE439441T1 (de) *	2000-02-23	2009-08-15	Life Technologies Corp	Veränderte, fluoreszierende proteine
AU2002243228B2 (en) *	2000-11-16	2007-08-02	The Regents Of The University Of California	Marine actinomycete taxon for drug and fermentation product discovery
FR2819721B1 (fr) *	2001-01-19	2005-02-04	L M D	Traitement des escarres avec sucre non metabolisable et un absorbant polymerique
MXPA03006565A (es) *	2001-01-23	2005-07-29	Gador Sa	Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.
EP1232746B1 (en) *	2001-02-14	2006-06-14	Forte IQ B.V.	Pharmaceutical composition comprising xanthan gum
ES2199202T3 (es)	2001-07-11	2004-02-16	Apr Applied Pharma Research S.A.	Granulados que contienen sustancias liposolubles y un procedimiento para su preparacion.
JP2005504815A (ja) *	2001-10-02	2005-02-17	スミスクライン・ビーチャム・コーポレイション	カルベジロールの新規組成物
GB0124953D0 (en) *	2001-10-17	2001-12-05	Novartis Ag	Organic Compounds
US7176232B2 (en)	2002-06-24	2007-02-13	The Regents Of The University Of California	Salinosporamides and methods for use thereof
AU2003261354A1 (en) *	2002-08-02	2004-02-23	The Regents Of The University Of California	New uses for inhibitors of inosine monophosphate dehydrogenase
US7112581B2 (en) *	2002-09-27	2006-09-26	Nereus Pharmaceuticals, Inc.	Macrocyclic lactams
GB0307553D0 (en) *	2003-04-01	2003-05-07	Novartis Ag	Organic compounds
US20050187170A1 (en) *	2003-06-16	2005-08-25	Biocryst Pharmaceuticals, Inc.	Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
US20050049294A1 (en) *	2003-06-20	2005-03-03	Michael Palladino	Methods of using [3.2.0] heterocyclic compounds and analogs thereof
NZ544858A (en) *	2003-06-20	2009-07-31	Univ California	Salinosporamides and methods for use thereof
US7727752B2 (en)	2003-07-29	2010-06-01	Life Technologies Corporation	Kinase and phosphatase assays
CA2445420A1 (en)	2003-07-29	2005-01-29	Invitrogen Corporation	Kinase and phosphatase assays
US7619059B2 (en)	2003-07-29	2009-11-17	Life Technologies Corporation	Bimolecular optical probes
WO2005025622A1 (ja) *	2003-09-12	2005-03-24	Ryukakusan Co. Ltd.	苦みマスキング粒状ゼリー飲料
AR045957A1 (es) *	2003-10-03	2005-11-16	Novartis Ag	Composicion farmaceutica y combinacion
US7087369B2 (en) *	2003-12-17	2006-08-08	The Regents Of The University Of California	Cornea preservation medium
KR20060132698A (ko) *	2004-01-23	2006-12-21	니리어스 파마슈티컬즈, 인코퍼레이션	항균제로 유용한 비스-인돌 피롤
US7683188B2 (en) *	2004-04-26	2010-03-23	TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság	Process for preparation of mycophenolic acid and ester derivatives thereof
EP1740563A2 (en) *	2004-04-27	2007-01-10	Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság	Mycophenolate mofetil impurity
NZ550910A (en)	2004-04-30	2011-06-30	Nereus Pharmaceuticals Inc	[3.2.0] Heterocyclic compounds and methods of using the same
US7579371B2 (en)	2004-04-30	2009-08-25	Nereus Pharmaceuticals, Inc.	Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US20050266031A1 (en)	2004-05-25	2005-12-01	Jay Dickerson	Pharmaceutical suspension composition
EP1768662A2 (en)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Small molecule immunopotentiators and assays for their detection
EP1765336A4 (en) *	2004-06-25	2010-03-10	Univ Johns Hopkins	ANGIOGENESIS INHIBITORS
JP2008506783A (ja) *	2004-07-20	2008-03-06	テバジョジセルジャールザ−トケルエンムケドレ−スベニュタ−ルシャシャ−グ	ミコフェノール酸ナトリウムの結晶形の調製方法
US20060051428A1 (en) *	2004-09-03	2006-03-09	Nelson Ayala	Aspartame and citrate flavored phosphate salt laxative
US20060093629A1 (en) *	2004-10-29	2006-05-04	Buehler Gail K	Dye-free pharmaceutical suspensions and related methods
US20070225350A1 (en) *	2004-12-03	2007-09-27	Anderson Kenneth C	Compositions and methods for treating neoplastic diseases
US20080280977A1 (en) *	2005-04-26	2008-11-13	Sandor Molnar	Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP2311795A3 (en)	2005-07-21	2011-12-28	Nereus Pharmaceuticals, Inc.	Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators
US20070082061A1 (en) *	2005-10-07	2007-04-12	Nelson Ayala	Reduction of saltiness with sweeteners
CA2640283A1 (en) *	2006-02-13	2007-08-23	Novartis Ag	High dosage of mycophenolic acid (mpa)
US7985429B2 (en)	2006-03-03	2011-07-26	C. B. Fleet Company, Inc.	Flavored colonic cleansing system
GB0612809D0 (en) *	2006-06-28	2006-08-09	Univ Sunderland	Formulation
US7998510B2 (en)	2006-08-17	2011-08-16	C. B. Fleet Company, Inc.	Low dose colonic cleansing system
FR2911506B1 (fr) *	2007-01-18	2009-07-03	Ceva Sante Animale Sa	Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
WO2008095195A2 (en) *	2007-02-02	2008-08-07	Nereus Pharmaceuticals, Inc.	Lyophilized formulations of salinosporamide a
US8999395B2 (en) *	2007-02-09	2015-04-07	Ceva Sante Animale	Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
US20090017167A1 (en) *	2007-07-11	2009-01-15	Herbalife International Inc.	Mixture and beverage made therefrom for protecting cellular hydration
JP5249941B2 (ja) *	2007-10-12	2013-07-31	株式会社龍角散	薬服用粒状ゼリー飲料及びその製造方法
TW200932240A (en)	2007-10-25	2009-08-01	Astellas Pharma Inc	Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8394816B2 (en) *	2007-12-07	2013-03-12	Irene Ghobrial	Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
MX2010012341A (es)	2008-05-12	2010-12-06	Nereus Pharmaceuticals Inc	Derivados de salinosporamida como inhibidores de proteasoma.
EP2310008A4 (en) *	2008-07-09	2014-03-05	Aspreva Internat Ltd	MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
CN101671706B (zh) *	2009-09-05	2013-09-18	山东新时代药业有限公司	一种霉酚酸发酵过程中补糖方法
AR078283A1 (es) *	2009-09-10	2011-10-26	Bial Portela & Ca Sa	Formulaciones de suspension oral de dibenzazepina carboxamidas
WO2011117883A1 (en) *	2010-03-23	2011-09-29	Alkem Laboratories Ltd.	Pharmaceutical composition of mycophenolate mofetil and process for preparing thereof
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
NZ737435A (en)	2013-03-14	2019-02-22	Alkermes Pharma Ireland Ltd	Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en)	2013-06-27	2015-10-27	Veloxis Pharmaceutical A/S	Regimen for suppressing organ rejection
EP3110793B1 (en)	2014-02-24	2019-08-21	Alkermes Pharma Ireland Limited	Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
CA2959965A1 (en)	2014-09-02	2016-03-10	Bhupinder Singh	Pharmaceutical formulations comprising tetrahydrocurcumin and lipids
IL312208A (en)	2014-10-08	2024-06-01	Pacific Northwest Res Institute	Methods and preparations for increasing the potency of antifungal agents
TW201615224A (zh) *	2014-10-24	2016-05-01	朗齊生物醫學股份有限公司	消化系統疾病用藥臨床新應用
US12011429B2 (en)	2016-06-02	2024-06-18	Steven Baranowitz	Prevention and treatment of viral infections
US10603299B2 (en)	2016-06-02	2020-03-31	Steven Baranowitz	Prevention and treatment of viral infections
CA3026241A1 (en)	2016-06-02	2017-12-07	Steven Baranowitz	Prevention and treatment of viral infections
US11918684B2 (en) *	2017-03-13	2024-03-05	Liqmeds Worldwide Limited	Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019191119A1 (en)	2018-03-28	2019-10-03	Herbalife International Of America, Inc.	Acetylation of polysaccharides
GB2591396B (en)	2018-08-18	2023-06-07	Ftf Pharma Private Ltd	Pharmaceutical suspension for oral dosage
CN112315962B (zh) *	2020-11-17	2022-03-29	北京化工大学	霉酚酸在治疗和预防柯萨奇病毒感染中的应用
CN117883379A (zh) *	2021-02-12	2024-04-16	浙江贝灵生物医药有限公司	一种口服碱性溶媒组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1157100A (en) *	1966-09-27	1969-07-02	Ici Ltd	Pharmaceutical Compositions
ZA717826B (en) *	1970-11-27	1973-06-27	Lilly Co Eli	Psoriasis treatment with mycophenolic acid
US3880995A (en) *	1973-05-14	1975-04-29	Lilly Co Eli	Treatment of arthritis with mycophenolic acid and derivatives
CA1146866A (en) *	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
CH653550A5 (de) *	1981-10-20	1986-01-15	Sandoz Ag	Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
US4727069A (en)	1987-01-30	1988-02-23	Syntex (U.S.A.) Inc.	Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en)	1987-01-30	1988-06-28	Syntex (U.S.A.) Inc.	Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
ATE166228T1 (de) *	1990-08-10	1998-06-15	Anormed Inc	Immunosuppressive zusammensetzungen
US5247083A (en)	1992-07-10	1993-09-21	Syntex (U.S.A.) Inc.	Direct esterification of mycophenolic acid

1994
- 1994-09-27 CN CN94193613A patent/CN1089583C/zh not_active Expired - Lifetime
- 1994-09-27 BR BR9407728A patent/BR9407728A/pt not_active Application Discontinuation
- 1994-09-27 JP JP51087695A patent/JP3844491B2/ja not_active Expired - Lifetime
- 1994-09-27 UA UA96041243A patent/UA39962C2/uk unknown
- 1994-09-27 EP EP94929902A patent/EP0721335B1/en not_active Expired - Lifetime
- 1994-09-27 CZ CZ1996954A patent/CZ291231B6/cs not_active IP Right Cessation
- 1994-09-27 NZ NZ274678A patent/NZ274678A/xx not_active IP Right Cessation
- 1994-09-27 ES ES94929902T patent/ES2248793T3/es not_active Expired - Lifetime
- 1994-09-27 DE DE69434474T patent/DE69434474T2/de not_active Expired - Lifetime
- 1994-09-27 SG SG1996001682A patent/SG55007A1/en unknown
- 1994-09-27 AT AT94929902T patent/ATE303143T1/de active
- 1994-09-27 PL PL94313772A patent/PL177323B1/pl unknown
- 1994-09-27 CZ CZ20021625A patent/CZ301771B6/cs not_active IP Right Cessation
- 1994-09-27 PT PT94929902T patent/PT721335E/pt unknown
- 1994-09-27 DK DK94929902T patent/DK0721335T3/da active
- 1994-09-27 RU RU96108965/14A patent/RU2150942C1/ru active
- 1994-09-27 AU AU79205/94A patent/AU678303B2/en not_active Expired
- 1994-09-27 WO PCT/US1994/010926 patent/WO1995009626A1/en active IP Right Grant
- 1994-09-27 EP EP04017608A patent/EP1475091A1/en not_active Withdrawn
- 1994-09-27 HU HU9600838A patent/HU228672B1/hu active IP Right Revival
- 1994-09-27 RO RO96-00701A patent/RO115412B1/ro unknown
- 1994-09-30 IL IL111116A patent/IL111116A/en not_active IP Right Cessation
- 1994-09-30 ZA ZA947683A patent/ZA947683B/xx unknown
- 1994-09-30 TW TW083109064A patent/TW427914B/zh not_active IP Right Cessation
1995
- 1995-03-29 US US08/412,645 patent/US5688529A/en not_active Expired - Lifetime
1996
- 1996-04-01 NO NO19961325A patent/NO310673B1/no not_active IP Right Cessation
- 1996-04-01 LV LVP-96-93A patent/LV11428B/en unknown
- 1996-04-01 FI FI961466A patent/FI116773B/fi not_active IP Right Cessation
- 1996-04-01 LT LT96-039A patent/LT4099B/lt not_active IP Right Cessation
1998
- 1998-12-19 HK HK98114091A patent/HK1012583A1/xx not_active IP Right Cessation
2006
- 2006-01-02 FI FI20060003A patent/FI117502B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0721335B1 (en)	2005-08-31
TW427914B (en)	2001-04-01
FI961466L (fi)	1996-04-01
LV11428B (en)	1996-12-20
AU7920594A (en)	1995-05-01
ES2248793T3 (es)	2006-03-16
RO115412B1 (ro)	2000-02-28
IL111116A0 (en)	1994-11-28
NO310673B1 (no)	2001-08-13
NO961325D0 (no)	1996-04-01
CZ301771B6 (cs)	2010-06-16
HK1012583A1 (en)	1999-08-06
FI116773B (fi)	2006-02-28
BR9407728A (pt)	1997-02-12
UA39962C2 (uk)	2001-07-16
FI961466A0 (fi)	1996-04-01
PL313772A1 (en)	1996-07-22
PL177323B1 (pl)	1999-10-29
CZ95496A3 (en)	1996-06-12
JPH09509648A (ja)	1997-09-30
LT96039A (en)	1996-10-25
WO1995009626A1 (en)	1995-04-13
LT4099B (en)	1997-01-27
FI20060003L (fi)	2006-01-02
CN1089583C (zh)	2002-08-28
DE69434474D1 (de)	2005-10-06
DE69434474T2 (de)	2006-05-18
HU228672B1 (en)	2013-05-28
LV11428A (lv)	1996-08-20
US5688529A (en)	1997-11-18
HUT73675A (en)	1996-09-30
JP3844491B2 (ja)	2006-11-15
EP1475091A1 (en)	2004-11-10
EP0721335A1 (en)	1996-07-17
FI117502B (fi)	2006-11-15
NZ274678A (en)	1999-07-29
CZ291231B6 (cs)	2003-01-15
ZA947683B (en)	1996-04-01
HU9600838D0 (en)	1996-05-28
RU2150942C1 (ru)	2000-06-20
ATE303143T1 (de)	2005-09-15
PT721335E (pt)	2005-11-30
CN1132479A (zh)	1996-10-02
NO961325L (no)	1996-04-01
SG55007A1 (en)	1998-12-21
AU678303B2 (en)	1997-05-22
IL111116A (en)	1998-04-05

Publication	Publication Date	Title
DK0721335T3 (da)	2006-01-09	Orale suspensioner med höj dosis af mycophenolat-mofetil
NO912758L (no)	1992-01-15	Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
DK0486499T3 (da)	1998-03-16	Stabile sammensætninger af ascorbinsyre
NO308848B1 (no)	2000-11-06	Kromanforbindelse og farmasøytisk preparat som inneholder den
FI95773B (fi)	1995-12-15	Menetelmä vesipitoisen, N-(3,4-dimetoksikinnamoyyli)antraniilihappoa sisältävän farmaseuttisen koostumuksen valmistamiseksi
MC1772A1 (fr)	1987-07-17	Derives de la quinoleine
DE69913116D1 (de)	2004-01-08	Orale flüssige lösung enthaltend das antidepressivum mirtazapine
FR2666508B1 (fr)	1994-02-18	Compositions pharmaceutiques contenant des derives de furanne.
ATE204752T1 (de)	2001-09-15	Therapeutische anwendungen von 2',5'- oligoadenylat-derivaten
ES2001856A6 (es)	1988-07-01	Una composicion acuosa basica de isotiazolonas n-insustituidas
SE8605050L (sv)	1987-05-27	Anvendning av tetrahydrobensotienylkarbamid-derivat som fungicider
CA2172506A1 (en)	1995-04-13	Mycophenolate mofetil and mycophenolic acid high dose oral suspensions
RU93051781A (ru)	1996-06-20	Бета -фенилизосерин-(2r,3s) и его соли, способ его получения и его применения
DK179986D0 (da)	1986-04-18	Racemiske og optisk aktive 1,12b-disubstituerede octahydroindolo(2,3-a)quinolizinderivater eller cis- og trans-isomere eller syreadditionssalte deraf, deres fremstilling og anvendelse som farmaceutika, mellemprodukter ved fremstillingen og disses fremstilling
ATE18554T1 (de)	1986-03-15	Optisch aktive imidazolylpropanol-verbindungen und deren herstellung und anwendung.
AR240915Q (es)	1991-03-27	Compuestos de brenzoilurea, procedimiento para prepararlos y compuestos intermediarios de aplicacion en dicho procedimiento y composiciones insecticidas que incluyen dichas benzoilureas como agente activo